Evidence map›Paper›PMID 42350367›Full record

ArticleBlood cancer journal2026

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

Shin Yeu Ong, Lu Chen, Jomel Meeko Manzano, Reid Merryman, Harsh Shah, Robert Stuver, Sanjal H Desai, Ann LaCasce, Ayo Falade, Kelsey Baron and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Shin Yeu OngDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.ORCID http://orcid.org/0000-0003-0192-6975
Lu ChenDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
Jomel Meeko ManzanoDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
Reid MerrymanDana-Faber Cancer institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6360-3234
Harsh ShahDivision of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Robert StuverDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sanjal H DesaiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-7892-2625
Ann LaCasceDana-Faber Cancer institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7349-0176
Ayo FaladeDana-Faber Cancer institute, Harvard Medical School, Boston, MA, USA.
Kelsey BaronDivision of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Nivetha GanesanDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tiffany ChangDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Urshila DuraniDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.ORCID http://orcid.org/0000-0003-1860-2424
Tamer OthmanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
Philippe ArmandDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-6098-1603
Matthew MeiDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-1109-6955
Alison J MoskowitzDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alex F HerreraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA. aherrera@coh.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Frontline therapy for classic Hodgkin Lymphoma (cHL) incorporating brentuximab vedotin (BV) improves outcomes compared with traditional chemotherapy, but up to 20% of patients relapse and need salvage treatment. Prior retrospective studies examining salvage therapies are mostly limited to patients who received chemotherapy-based treatment in frontline without novel agents. We evaluated outcomes in 116 patients with relapsed/refractory (R/R) cHL who received brentuximab and anthracycline-containing frontline treatment. High risk factors at relapse or progression were common, including primary refractory disease (62%), advanced stage (63%), and extranodal disease (46%). At first salvage, 73% of patients received PD-1 blockade (58% in conjunction with chemotherapy), and 81% received PD-1 blockade at any salvage line. Overall, 78% of patients proceeded to ASCT. With a median follow-up of 19 months, the 2-year PFS and OS from the start of salvage in all patients were 61% and 97% respectively. Among patients with ASCT, the 2-year post-transplant PFS (PFS

Indexed as

Antineoplastic Agents, ImmunologicalBrentuximab VedotinHodgkin DiseaseAdolescentAdultAgedFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalRecurrenceRetrospective StudiesSalvage TherapyTreatment OutcomeYoung AdultAntineoplastic Agents, ImmunologicalBrentuximab Vedotin

Identifiers

PMID42350367
PMCPMC13558693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.